Question 1

What are the potential benefits of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects clinical trial (NCT00888069). Contact the study team or your healthcare provider for specific answers.

Question 2

How does CTAP101 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects clinical trial (NCT00888069). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from CTAP101?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects clinical trial (NCT00888069). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects clinical trial (NCT00888069). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests will be done during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects clinical trial (NCT00888069). Contact the study team or your healthcare provider for specific answers.

Question 6

How will this study impact my overall treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects clinical trial (NCT00888069). Contact the study team or your healthcare provider for specific answers.

What this study is about